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findings suggest that chronic allograft injury in F344!LEWRenal allograft protection with losartan in Fisher!Lewis rats:
rats is, to a large extent, mediated by angiotensin II-dependentHemodynamics, macrophages and cytokines.
mechanisms and that these involve glomerular hemodynamics,Background. We sought to assess the effects of angiotensin
macrophages, and macrophage-associated cytokines.receptor blockade on glomerular hypertension, macrophage
recruitment, and cytokine expression, all of which contribute
to the development of chronic graft injury in this model.
Methods. The effects of treatment with the specific angioten-
Recent experimental and clinical evidence emphasizessin II type 1 (AT1) receptor antagonist, losartan, were assessed
contributions from both antigen-independent and anti-over 24 weeks in F344!LEW rats (LOS, N 5 9) versus vehicle-
treated F344!LEW controls (CON, N 5 9). gen-dependent factors in the pathogenesis of chronic
Results. UprotV rose progressively in CON (from 7.0 6 2.9 renal allograft failure [1–6]. A growing body of data
to 41 6 17 mg/day at 24 wk) but remained at baseline in LOS also implicates injury processes associated with extensive(4.2 6 0.6 to 9.4 6 1.3 mg/day, P , 0.05 vs. CON). Glomerular
nephron loss as a significant determinant of progressivecapillary pressure (PGC) was increased in CON (71 6 1 mm
graft injury in the F344!LEW rat model of late renalHg at week 20), but remained within the normal range in LOS
rats (54 6 2 mm Hg, P , 0.05). Glomerulosclerosis averaged allograft failure. Increased glomerular capillary hydrau-
0.3 6 0.2% in LOS versus 4 6 2% in CON rats (P , 0.05). lic pressure ("PGC) [7–9] and glomerular hyperfiltrationTubulointerstitial injury was minimal in both LOS and CON [8, 9] have been observed in F344!LEW rats, suggestingrats (1). The overexpression of renal cortical cytokine mRNA
that chronic glomerular injury in this model is driven,levels for the monocyte chemoattractants, monocyte chemoat-
tractant protein-1 (MCP-1) and RANTES, as well as interleu- at least in part, by glomerular hemodynamic factors.
kin-1, inducible nitric oxide synthase, and transforming growth Evidence supporting this view came from studies con-
factor-b, assessed by competitive reverse transcription-poly- ducted in our laboratories showing that restoring total
merase chain reaction, was suppressed in LOS versus CON
recipient kidney mass essentially normalized PGC andrats at 20 weeks. Macrophage and T-cell numbers were de-
markedly reduced chronic allograft injury [4, 9].creased, and MCP-1, RANTES, and intercellular adhesion
molecule-1 staining in the graft, identified by immunohisto- In a variety of experimental models of chronic renal
chemistry, were attenuated in LOS versus CON rats. disease (CRD), elevated PGC is maintained, in part, by
Conclusions. The renoprotective effects of losartan in increased local angiotensin II (Ang II) activity. Pharma-F344!LEW rats were associated with lowered PGC, inhibition
cological interruption of the renin-angiotensin systemof macrophage chemoattractants and recruitment, and suppres-
(RAS) either by angiotensin-converting enzyme inhibi-sion of macrophage-associated cytokines at 20 weeks. These
tors (ACEI) [10] or angiotensin II type 1 (AT1) receptor
antagonists (AT1RAs) [11, 12] has been shown to be1Current address: Department of Surgery, UCLA, Los Angeles, CA, highly effective in reducing renal injury in experimentalUSA.
models of CRD. Agents that inhibit the RAS have also2Current address: Department of Pediatrics, Children’s Hospital Medi-
cal Center, Boston, MA, USA. been shown to limit chronic renal allograft injury in
F344!LEW rats [13–15], although sometimes at levels ofKey words: chronic rejection, angiotensin II, transplantation, kidney
injury. systemic blood pressure below the autoregulatory range
[13]. However, in addition to its hemodynamic effects,
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fibrogenic growth factor transforming growth factor-b the measured arterial pressure of the rat with 1.25%
glutaraldehyde in 0.1 mol/L cacodylate buffer (pH 7.4)(TGF-b) in cultured renal cells [16] and overexpression
of cytokines and chemoattractant molecules such as and processed for morphologic studies. The frequency
of focal and segmental glomerulosclerosis (FSGS) wasmonocyte chemoattractant protein-1 (MCP-1) [17, 18].
Chronic infusion of Ang II at subpressor doses also leads determined by examining all glomerular profiles (.100)
contained in one or two coronal sections from each ratto perivascular fibrosis of arterioles [19]. Proinflamma-
tory cytokines and profibrotic growth factors are thought stained using the periodic acid-Schiff method. The num-
ber of glomeruli showing criteria for sclerosis [23] wasto play a major role in the pathogenesis of chronic renal
allograft injury [20–22]. Several are involved in macro- expressed as a percentage of the total examined per
rat by an experienced pathologist (H.G.R.), who wasphage recruitment; others are characteristic products of
activated macrophage but may be synthesized by renal blinded as to the group from which the sections came.
cells under certain circumstances. We therefore hypothe-
Glomerular hemodynamic studiessized that chronic treatment of F344!LEW rats with
the AT1RA losartan would lower glomerular capillary In two additional groups of identically prepared
F344!LEW-transplanted rats receiving either losartanpressures (PGC), ameliorate proteinuria, reduce macro-
phage recruitment, and retard the development of chronic (50 mg/L, N 5 6) in their drinking water or drinking
water alone (N 5 6), micropuncture and gene expressionrenal allograft injury. We further hypothesized that the
identification of those cytokines in which the expression studies were carried out at 20 weeks. The dose of losartan
was lowered in this group in order to maintain SBP .is modified by losartan would help reveal key molecular
mediators of chronic allograft injury in this model. 100 mm Hg and to avoid hypotension under anesthesia.
For these studies, anesthesia was induced with metho-
hexital (10 to 20 mg/kg, IV) and maintained with a slow
METHODS
bolus injection of Inactin (0.1 mL/100 g body wt, IV;
Kidney transplantation was carried out between male Byk Gulden, Konstanz, Germany). After the induction
Fisher 344 donors and male Lewis recipients under ether of anesthesia, the rats were placed on a thermostatically
anesthesia. The left kidney of each donor was isolated, regulated table. A standard surgical preparation for mi-
excised, cooled, and then positioned orthotopically in cropuncture was employed. A femoral artery catheter
Lewis recipients of similar age and body weight. Vascular was inserted for blood pressure measurement and collec-
and ureteric anastomoses were fashioned end-to-end us- tion of blood (250 mL) for baseline as well as intermittent
ing 10-0 prolene sutures and without stenting. The recipi- sampling of plasma protein concentration (CA), hemato-
ents underwent ipsilateral (native) uninephrectomy at crit (Hct), and plasma inulin concentration. Two cathe-
the time of transplantation; the contralateral native kid- ters were inserted into the femoral vein for administra-
ney was removed on the seventh postoperative day. All tion of Inactin and constant infusion of the following
rats received low dose cyclosporine A (5 mg/kg/day IM) solutions throughout the experiments: bovine salt-poor
until the 10th postoperative day to suppress an early albumin (40 g/L) at 100 mL/min to replace protein and
episode of acute rejection; they then went on to survive volume losses during surgery (0.5% body wt), 7.5% inu-
for prolonged periods but with progressive evidence of lin, and 0.75% para-aminohippurate (Merck, Rahway,
chronic rejection [20, 21]. From week 3 onward, recipient NJ, USA) in 0.9% saline at 27 mL/min. The left kidney
animals received losartan (60 mg/L) in the drinking water was then exposed through a midline incision, and the
(LOS, N 5 9) or no treatment (CON, N 5 9). All rats ureter was catheterized. Following a 60-minute stabiliza-
were housed under standard conditions, receiving stan- tion period, timed urine collections were obtained for
dard rodent chow (Purina 2001) and water ad libitum, determination of the whole-kidney glomerular filtration
and were treated in accordance with National Institutes rate (GFR). During these periods, four exactly timed
of Health guidelines for the care and use of laboratory proximal tubule fluid samples were collected for determi-
animals. nation of single nephron GFR (SNGFR). At the mid-
point of the periods, arterial blood was sampled for mea-
Chronic studies surement of CA and plasma inulin concentration.
At three-week intervals, body weight, systolic blood Hydraulic pressures were then measured in four to six
pressure (SBP), and urinary protein excretion rates proximal tubules under free-flow (PT) and stop-flow (PSF)
(UprotV) were determined. SBP was assessed using the conditions. Stop-flow conditions were created upstream
tail-cuff method, and UprotV was determined by the sulfo- of single nephron obstructions produced by microinjec-
salicylic acid method on 24-hour urine samples collected tion of bone wax into proximal tubule segments. Pressure
from metabolic cages. At the conclusion of the chronic measurements were obtained using micropipettes of 1
studies, all rats were anesthetized with pentobarbital (50 to 2 mm tip diameter filled with 2 mol/L NaCl connected
to a servo-null pressure measuring device (Instrumenta-mg/kg IP), and the left kidney was perfusion fixed at
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tion for Physiology and Medicine, San Diego, CA, USA). tested for individual cytokine mRNA transcripts as well
as for the control b-actin mRNA transcript. Band inten-CA was determined using a clinical refractometer; arterial
plasma colloid osmotic pressure, PA, was derived from sity for each cytokine was adjusted for expression of b-
actin. Twofold differences were detectable. This methodCA using the Landis-Pappenheimer equation. PGC was esti-
mated from PSF 1 PA and DP from PGC 2 PPT. Urine has been noted to be as accurate as scintillation counting
of 32P-labeled PCR products [27]. Each PCR reactionvolumes were determined gravimetrically. Concentra-
tions of inulin in blood and plasma were assessed by an was repeated twice in all samples and did not differ
appreciably from one another.anthrone method [24] and in tubule fluid samples by a
microimmunofluorescence method [25].
ImmunohistologyAt the end of the study, portions of renal allograft
cortex were excised, snap-frozen in liquid nitrogen, and Mouse monoclonal antibodies to rat monocytes/mac-
rophages (ED-1) and to the rat intercellular adhesionstored at 2808C for later RNA extraction. Coronal sec-
tions were frozen in gel (OCT; Sakura Finetek, Torrance, molecule-1 (ICAM-1; CD54) and to T cells (directed
against the T-cell receptor a/b chains) were obtainedCA, USA) for later examination by immunohistochem-
istry. from Bioproducts for Science (Indianapolis, IN, USA);
TNF-a, TGF-b, RANTES, and MCP-1 were from Gen-
Reverse transcription-polymerase chain reaction zyme (Boston, MA, USA). Biontinylated donkey anti-
mouse IgG and streptavidin peroxidase-conjugated com-Total RNA was extracted from frozen kidney cortex
samples using a guanidinium isothiocyanate/phenol- plexes were obtained from Dako (Carpenteria, CA,
USA). Cryostat sections (4 mm) of cortical samples werechloroform isolation method (ULTRA-spec.; Biotex,
Houston, TX, USA) [23]. The isolated total RNA was air fixed in acetone and then incubated (room temperature,
1 h) with a blocking solution [Tris-buffered saline (TBS)dried and resuspended in diethyl pyrocarbonate-treated
water, and the approximate quantity of RNA was deter- with 1% nonfat milk, 0.05% Tween 20, 0.02% sodium
azide and 1058C heat-inactivated donkey serum]. Opti-mined by spectrophotometry (O.D. 260). The purity of
the RNA was then confirmed with an O.D. 260/280 ratio mally diluted primary monoclonal antibodies (mAbs; 0.1
mol/L TBS containing 1% nonfat milk, 0.05% Tweenfor all samples more than 1.8. Total RNA (2.5 mg) was
used for first-strand cDNA synthesis employing 1.2 mg 20, and 0.02% sodium azide) were then used (room tem-
perature, 1 to 24 h), followed by incubation with bridgingof oligo (dT)12–18 and the superscript reverse transcriptase
(RT) method according to manufacturer’s recommenda- antibodies and peroxidase-conjugated complexes. Con-
trol sections were prepared by replacing the primarytions (GIBCO-BRL, Gaithersburg, MD, USA). Non-
looping, nonoverlapping, oligonucleotide primer pairs mAb with either dilution buffer or normal mouse serum.
The peroxidase reaction was developed with 3,3-diami-from separate exons were obtained for each gene stud-
ied, including b-actin, from Clontech (Palo Alto, CA, nobenzidine tetrahydrochloride (Sigma, St. Louis, MO,
USA). Stained sections were evaluated in duplicate orUSA) or Genosys (The Woodlands, TX, USA). The
specific primers for interleukin-2 (IL-2), interferon-g triplicate by counting the labeled cells within 10 high-
power fields (HPFs)/section or by analysis in semiquanti-(IFN-g), IL-1, IL-6, TGF-b, tumor necrosis factor-a
(TNF-a), RANTES, MCP-1, and b-actin followed pre- tative fashion in which the relative abundance of each
one was judged from (1) minimal to (111) very abun-viously published sequences [22]. The primer sequence
for endothelin was as follows: 59-GCTATGAATCGAT dant.
CCGAT-39 and 59-CATGGATCACTGCCCTAA-39.
Statistical analysisCompetitive polymerase chain reaction (PCR) for
semiquantitation of mRNA was performed as reported Statistical comparisons between groups were made us-
ing factorial or repeated-measures analysis of variancepreviously [26]. Briefly, for each 25 mL amplification, 2.5
mL of first-strand cDNA product was used. Twofold to (ANOVA), with post hoc testing where appropriate [26].
FSGS scores were compared using a Wilcoxon test andtenfold serial dilutions of known quantities of PCR
MIMICs were added to the PCR reaction containing RT-PCR data by the Mann–Whitney method. Data are
presented as mean 6 SEM unless stated otherwise. Theconstant amounts of sample target cDNA. RT-PCR con-
ditions were optimized for each cytokine and growth null hypothesis was rejected at P , 0.05.
factor amplified. PCR products (5 mL) were run on an
ethidium bromide-stained 1.5% agarose gel, and gene-
RESULTS
specific bands were visualized and photographed under
Graft function and morphologyultraviolet light. The quantities of MIMIC and target
cDNA were compared by band-intensity analysis using As shown in Table 1, all rats grew at similar rates
without significant differences in body weights betweena PC SCANJET and NIH Image and Adobe Photoshop
software (Adobe Inc., San Jose, CA, USA). Tissues were the LOS and CON groups. Rats receiving losartan aver-
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Table 1. Body weight in the two groups of rats over 24 weeks
Week
Body weight g 6 9 12 15 18 21 24
Losartan (N 5 9) 291611 32466.5 34066.8 34668.8 34767.0 36865.6 36765.9
Control (N 5 9) 29269.9 30967.3 33065.5 348612 358610 368613 367610
Data are mean 6 SEM. No statistically significant differences between groups was found by repeated measures ANOVA.
Table 2. Systolic blood pressure (SBP) in the study groups over 24 weeks
Week
SBP mm Hg 6 9 12 15 18 21 24
Losartan (N 5 9) 8664.8a 9664.1a 10264.6 9664.4a 11165.1 11063.4 11363.6
Control (N 5 9) 12265.7 12468.3 12064.0 12164.0 12167.0 12467.0 11966.0
Data are mean 6 SEM.
aP , 0.05 vs. control by repeated measures ANOVA and by Scheffe´’s test
Fig. 2. Glomerulosclerosis. The percentage of glomeruli involved with
focal and segmental glomerulosclerosis (FSGS) is depicted in a box and
whiskers plot. The horizontal margins of the box represent the 75thFig. 1. Proteinuria. Symbols are: ( ) losartan group; (j) control
percentile, and the error bars represent the 90th percentile. The circlesgroup. Progressive rises in urinary protein excretion rates seen in the
denote the range. FSGS in vehicle-treated rats (Control) was character-control rats are abolished in rats receiving losartan. *P , 0.05 by
ized by a high variance, whereas the losartan rats showed little varianceANOVA and Scheffe´’s test.
in sclerosis with four rats scoring zero. Because of the unequal variances
between the groups, nonparametric testing was used for statistical com-
parison (Wilcoxon test, *P , 0.05).
aged SBPs that were initially lower when compared with
controls, although at weeks 12 and 18 through 24, levels
(Fig. 2), with the percentage of glomeruli affected byof SBP in LOS rats rose to approximate those of CON
FSGS averaging 0.3 6 0.2% in LOS versus 4 6 2% inrats, which remained normotensive throughout the study
CON rats (P , 0.05 by Wilcoxon test). Four of the nine(Table 2). As depicted in Figure 1, progressive increases
rats in the LOS group showed no evidence of glomerularin UprotV were observed over 24 weeks in CON rats,
injury whatsoever.whereas in LOS rats, UprotV remained at levels that were
essentially normal and significantly lower than those ob-
Hemodynamic studiesserved in CON (F 5 6.6, P , 0.05 by repeated-measures
ANOVA). In keeping with the prevention of proteinuria For the hemodynamic studies, the losartan dose was
adjusted in an attempt to minimize differences in SBPsin LOS rats, structural injury was also less at 24 weeks
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Table 3. Systolic blood pressure (SBP) over 20 weeks interstitial areas was clearly diminished in LOS rats (av-
eraging 21 vs. 31 in controls), staining patterns forWeek
TNF-a, TGF-b, and platelet-derived growth factorSBP mm Hg 6 12 20
(PDGF), while abundant in tubulointerstitial regions and
Losartan (N 5 6) 8764.5a 10665.4 10766.3
present in glomeruli, were highly variable, and no clearControl (N 5 6) 10862.9 11367.3 12362.9
differences could be discerned between the LOS andData are mean 6 SEM.
aP , 0.05 versus control by repeated measures ANOVA and by Scheffe´’s test CON rats.
DISCUSSION
between the two groups (Table 3). Nevertheless, at 20 Chronic renal allograft failure remains a major obsta-
weeks, mean arterial pressure (MAP), measured under cle to transplantation fulfilling its promise as the treat-
anesthesia, was still significantly lower in LOS rats than ment of choice for end-stage renal disease [28]. Thus,
CON (Table 4) but was within the autoregulatory range. there is an urgent need to identify mechanisms of chronic
Accordingly, GFR was undiminished in LOS rats at this renal allograft injury to provide the basis for developing
lower MAP. Average values for renal plasma flow rates therapeutic strategies to enhance graft longevity and pre-
and filtration fraction were also similar between LOS and serve adequate renal allograft function. Several lines of
CON rats. SNGFR showed a nonsignificant tendency to evidence suggest that antigen-independent mechanisms
be lower in LOS versus CON rats, and both values were play a major role in the progression of chronic renal
elevated when compared with values of SNGFR ob- allograft “rejection” [1–6]. Since the involvement of RAS-
tained in this laboratory from age-matched, ungrafted dependent mechanisms is a consistent finding in a diver-
normal rats (40 nL/min). Average values for PGC were sity of models of experimental CRD, pharmacological
elevated in CON rats to levels consistent with glomerular interruption of this system is an obvious candidate ap-
capillary hypertension (Table 4), despite MAP in these proach for preservation of renal allograft function. More-
rats remaining within the normotensive range. Treat- over, our previous work has demonstrated the impor-
ment with losartan was associated with significantly low- tance of inadequate nephron mass to the development
ered values for PGC and DP, the glomerular transcapillary of chronic allograft failure in this model [4], providing
hydraulic pressure difference, when compared with CON. a clear rationale for using pharmacological interruption
Values for LOS rats approximated values typically ob- of the RAS to reduce PGC and slow the pace of disease
tained from normal unoperated, two-kidney rats in our progression.
laboratory (55 mm Hg). The data clearly show that losartan administration pre-
vents the development of proteinuria in F344!LEW
Intragraft expression studies rats over the 24 weeks of the study. Although SBP was
Reverse transcription-polymerase chain reaction stud- initially lower in rats receiving LOS versus CON, the
ies on allograft cortex revealed an unambiguous effect differences abated such that after week 15, the values
of losartan treatment on the expression of a variety of were not significantly different. Using a slightly lower
cytokines implicated in the development of chronic renal dose of losartan, at week 20, under anesthesia, PGC ap-
allograft injury in this model. Expression of RANTES, proached the normal ranges in LOS rats, whereas in
inducible nitric oxide synthase (iNOS), IL-1, IL-6, TGF-b, untreated rats, it remained markedly elevated. This is
ET, and MCP-1, associated with macrophage activity, consistent with a losartan-dependent lowering of PGC
were all significantly reduced (Fig. 3). Interestingly, lev- with more modest reductions of arterial pressure than
els of expression of IL-2, IFN-g, and TNF-a were not those observed in previous reports with AT1 receptor
significantly affected by treatment and did not differ blockade [13]. These favorable changes in PGC were asso-
significantly between CON and LOS rats. Immunohisto- ciated with a marked reduction in structural injury to
chemical analysis revealed characteristic features of the allograft, as assessed by the glomerulosclerosis score.
chronic rejection in kidney allografts in CON rats, includ- The scores for the tubulointerstitial injury were not dif-
ing mononuclear cell infiltration in perivascular and in- ferent in the LOS versus CON rats (1 by semiquantita-
terstitial areas and early arteriosclerosis, as well as early tive scoring). These findings suggest that the renoprotec-
glomerular injury. Sections of allografts from losartan- tive effects of AT1 receptor blockade could be mediated
treated rats, on the other hand, showed markedly fewer by a reduction of glomerular and tubulointerstitial injury
mononuclear cells, with ED-11 cell numbers averaging initiated by elevated PGC. An alternative but not mutually
52 6 9 cells per 10 HPFs in LOS versus 112 6 10 in exclusive pathway to injury could involve angiotensin-
CON (P , 0.05) and T-cell numbers averaging 47 6 7 dependent fibrogenesis or potentiation of antigen-spe-
in LOS versus 86 6 10 in CON rats (P , 0.05; Table 5). cific injury processes. Indeed, Benediktsson et al ob-
served protective effects from pharmacological inhibi-Whereas RANTES, MCP-1, and ICAM-1 staining in
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Table 4. Renal physiological parameters at 20 weeks of study
Psf PT PA PGC DPMAP GFR SNGFR RPF CA
mm Hg mL/min nL/min mL/min FF g/dL mm Hgmm Hg
Losartan Mean 107a 1.84 60 7.1 0.26 38a 13 5.2 16 54a 41a
(N 5 6) SEM 5 0.27 8.2 0.57 0.04 2 1 0.12 0.6 2.4 2.5
Control Mean 132 1.91 83 7.3 0.25 53 12 5.6 18 71 59
(N 5 6) SEM 3 0.36 8.7 1.28 0.03 1 1 0.11 0.5 1.2 1.2
Abbreviations are: MAP, mean arterial pressure; GFR, whole kidney glomerular filtration rate; SNGFR, single nephron glomerular filtration rate; RPF, renal
plasma flow; FF, filtration fraction; PSf, tubular stop flow pressure; PT, tubular free flow pressure; CA, afferent arteriolar plasma protein concentration; PA, afferent
arteriolar oncotic pressure; PGC, glomerular capillary pressure; DP, glomerular transcapillary pressure difference.
aP , 0.05 versus control by ANOVA and Scheffe´’s test
Table 5. T-cell and macrophage numbers
SBP mm Hg T cells CD-1 MO
Losartan (N 5 6) 4767a 5269a
Control (N 5 6) 86610 112610
Data are mean 6 SEM.
aP , 0.05 vs. control by Mann–Whitney
local macrophage recruitment in the allograft. Macro-
phages also express angiotensin receptors [31], and an-
giotensin has been shown to stimulate macrophage re-
cruitment directly [32]. From our data, however, it is not
possible to determine whether losartan has had a direct
effect on macrophage activation in the F344!LEW renal
allograft. However, our findings may be considered con-
sistent with Ang II-stimulated transcriptional activation
of ICAM-1, RANTES, and MCP-1, with resulting en-
hanced recruitment, activation, and intragraft retention
of macrophages. In turn, the expanded macrophage pop-
ulation could account for the increased transcription of
Fig. 3. Allograft renal cortical gene expression by semiquantitative iNOS, IL-1, IL-6, and TGF-b that was detected. Macro-
RT-PCR. Levels of expression of RANTES, interleukin (IL)-1, IL-6, phages have been implicated as important contributors
transforming growth factor-b (TGF-b), inducible nitric oxide synthase
to graft injury in this model. Inhibition of macrophage(iNOS), endothelin-1 (ET-1), and monocyte chemoattractant protein-1
(MCP-1) were all reduced significantly in losartan rats. Expression of function ameliorated graft injury [33], whereas interven-
tumor necrosis factor-a (TNF-a) and the classic T-cell products IL-2, tions designed to increase macrophage activation exacer-
interferon-g (IFN-g), by contrast, were unaffected in losartan rats.
bated chronic graft injury [34].Symbols are: ( ) losartan; (j) control. *P , 0.05 by Mann–Whitney
test. Levels of expression of these molecules under normal conditions While the previously mentioned observations are con-
in rat renal cortex are all , 0.5. sistent with the hypothesis that Ang II contributes di-
rectly to the up-regulation of renal cortical cytokine ex-
pression characteristic of this model, it is possible that
Ang II exerts these effects via altered hemodynamics.tion of the RAS beyond those attributable to beneficial
Recent in vitro evidence raises the possibility that thehemodynamic effects [13].
transduction of mechanical forces by mesangial andAngiotensin II stimulates the synthesis and elabora-
other cell types present in the kidney may lead to in-tion of extracellular matrix components by glomerular
creased cytokine expression [35]; this may be analogousmesangial cells in culture [16]. Interestingly, recent evi-
to the recent in vivo observation that systemic hyperten-dence also suggests that Ang II may promote the synthe-
sion up-regulates the expression of MCP-1 in the vascularsis of a variety of cell-adhesion molecules and cytokines,
smooth muscle cells of rats [36]. Thus, altered glomerularpossibly via reactive oxygen intermediates [29, 30] and
hemodynamics, for example, increased PGC, could haveactivation of the transcription factor nuclear factor-kB
a direct effect on gene expression in the kidney. It has(NF-kB) [17, 18]. Molecules with NF-kB-responsive ele-
also been suggested that the increased uptake of filteredments include ICAM-1 and MCP-1. Coordinated expres-
sion of these latter factors might be expected to promote protein by the renal tubule epithelial cells in proteinuric
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4. Mackenzie HS, Tullius SG, Heemann UW, Azuma H, Rennkestates may stimulate local cytokine expression [37, 38].
HG, Brenner BM, Tilney NL: Nephron supply is a major determi-
Accordingly, the favorable hemodynamic effects of lo- nant of long-term renal allograft outcome in rats. J Clin Invest
94:2148–2152, 1994sartan could also alter the expression of proinflammatory
5. Tullius SG, Hancock WW, Heemann U, Azuma H, Tilney NL:cytokines in renal cortex by reducing the passage of
Reversibility of chronic renal allograft rejection: Critical effect of
proteins through the glomerular filtration barrier and time after transplantation suggests both host immune dependent
and independent phases of progressive injury. Transplantationreducing their uptake by the renal tubules. Finally, it is
58:93–99, 1994possible that losartan blocks direct actions of Ang II on
6. Terasaki PI, Cecka JM, Gjertson DW, Takemoto S: High survival
tubule cells to promote cytokine expression and elabo- rates of kidney transplants from spousal and living unrelated do-
nors. N Engl J Med 333:333–336, 1995rate extracellular matrix components [39, 40].
7. Kingma I, Chea R, Davidoff A, Benediktsson H, Paul LC: Glo-While it is apparent that the RAS, either directly or
merular capillary pressures in long-surviving rat renal allografts.
indirectly, is involved prominently in injury processes Transplantation 56:53–60, 1993
8. Junaid A, Kren SM, Rosenberg ME, Nath KA, Hostetter TH:and macrophage recruitment and activation in this model,
Physiological and structural responses to chronic experimental re-we do not see any evidence to support an interaction of
nal allograft injury. Am J Physiol 267:F1102–F1106, 1994
the RAS with T-cell activation at this late stage, insofar 9. Mackenzie HS, Azuma H, Troy JL, Rennke HG, Tilney NL,
Brenner BM: Augmenting kidney mass at transplantation abro-as the levels of expression of IFN-g and IL-2, classic
gates chronic renal allograft injury in rats. Proc Assoc Am Physi-products of activated T cells, are similar in LOS rats when
cians 108:128–133, 1996
compared with controls at 20 weeks. Previous studies 10. Anderson S, Meyer TW, Rennke HG, Brenner BM: Control
of glomerular hypertension limits glomerular injury in rats withsuggest that the influence of T cells occurs earlier in
reduced renal mass. J Clin Invest 76:612–619, 1985this model; therefore, it is possible that an angiotensin-
11. Lafayette RA, Mayer G, Park SK, Meyer TW: Angiotensin II
dependent effect on T-cell activation would be evident receptor blockade limits glomerular injury in rats with reduced
renal mass. J Clin Invest 90:766–771, 1992at earlier time points or that the sensitivity of the RT-
12. Mackenzie HS, Ots M, Ziai F, Lee KW, Kato S, Brenner BM:PCR for IFN-g and IL-2 is compromised because of low
Angiotensin receptor antagonists in experimental models of
levels of expression of these factors. The finding of signifi- chronic renal failure. Kidney Int 52(Suppl 63):S140–S143, 1997
13. Benediktsson H, Chea R, Davidoff A, Paul LC: Antihyperten-cantly fewer T cells in the LOS allografts versus CON
sive drug treatment in chronic renal allograft rejection in the rat:rats could be consistent with this latter interpretation. Effect on structure and function. Transplantation 62:1634–1642,
In summary, these data show that the AT1RA losartan 1996
14. Mackenzie HS, Ziai F, Nagano H, Azuma H, Troy JL, Rennkeis effective in reducing PGC and proteinuria in long-sur-
HG, Tilney NL, Brenner BM: Candesartan cilexetil reducesviving F344!LEW renal allografts. These effects are chronic renal allograft injury in Fisher!Lewis rats. J Hypertens
associated with a reduction in allograft macrophage in- 15(Suppl 6):21–25, 1997
15. Amuchastegui SC, Azzollini N, Mister M, Pezzotta A, Pericofiltration and attenuated expression of molecules in-
N, Remuzzi G: Chronic allograft nephropathy in the rat is im-volved in macrophage recruitment. Together with the proved by angiotensin II receptor blockade but not by calcium
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